We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 29 juni 2018

Latest content from npj Vaccines: 28 June 2018

If you are unable to see the message below, click here to view.
npj Vaccines

Table of Contents: June 2018

Comment | 28 June 2018

AS03 stresses out macrophages: Commentary on 'Activation of the endoplasmic reticulum stress sensor IRE1a by the vaccine adjuvant AS03 contributes to its immunostimulatory properties'

Mark T. Orr & Christopher B. Fox

npj Vaccines 3 , Article number: 27 |  doi: 10.1038/s41541-018-0070-8

Article | 28 June 2018

Activation of the endoplasmic reticulum stress sensor IRE1a by the vaccine adjuvant AS03 contributes to its immunostimulatory properties

Charlotte Givord, Iain Welsby, Sophie Detienne, Séverine Thomas, Assiya Assabban et al.

npj Vaccines 3 , Article number: 20 |  doi: 10.1038/s41541-018-0058-4

Article | 21 June 2018

Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations

Willem M. Kühtreiber, Lisa Tran, Taesoo Kim, Michael Dybala, Brian Nguyen et al.

npj Vaccines 3 , Article number: 23 |  doi: 10.1038/s41541-018-0062-8

Perspective | 11 June 2018

Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation

Alan D. T. Barrett

npj Vaccines 3 , Article number: 24 |  doi: 10.1038/s41541-018-0061-9

Article | 05 June 2018

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica

Mayuresh M. Abhyankar, Mark T. Orr, Susan Lin, Mohammed O. Suraju, Adrian Simpson et al.

npj Vaccines 3 , Article number: 22 |  doi: 10.1038/s41541-018-0060-x

Article | 30 April 2018

FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge

Craig Miller, Mauren Emanuelli, Elizabeth Fink, Esther Musselman, Ryan Mackie et al.

npj Vaccines 3 , Article number: 16 |  doi: 10.1038/s41541-018-0051-y

Your email address is in the npj Vaccines mailing list.
You have been sent this alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: myaccount (You will need to log in to be recognised as a nature.com registrant)
For further technical assistance, please contact our registration department
For print subscription enquiries, please contact our subscription department
For other enquiries, please contact our customer feedback department
Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA
Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Springer Nature